Bausch Health Cos (NYSE:BHC) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Bausch Health Cos (NYSE:BHC) from a buy rating to a strong-buy rating in a research note issued to investors on Saturday morning.

Several other equities research analysts also recently issued reports on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Bausch Health Cos in a research note on Monday, December 29th. Truist Financial raised their target price on Bausch Health Cos from $7.00 to $8.00 and gave the company a “hold” rating in a research note on Wednesday, January 7th. Raymond James Financial reiterated a “market perform” rating on shares of Bausch Health Cos in a research note on Monday, January 26th. Finally, Barclays began coverage on Bausch Health Cos in a research note on Monday, December 8th. They set an “equal weight” rating and a $8.00 price objective for the company. Five equities research analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $8.67.

Bausch Health Cos Stock Up 1.9%

NYSE BHC opened at $5.99 on Friday. The company has a quick ratio of 0.97, a current ratio of 1.30 and a debt-to-equity ratio of 57.48. Bausch Health Cos has a fifty-two week low of $4.25 and a fifty-two week high of $8.69. The business has a 50 day moving average price of $6.79 and a two-hundred day moving average price of $6.71. The stock has a market cap of $2.22 billion, a PE ratio of 6.18 and a beta of 0.42.

Institutional Trading of Bausch Health Cos

Institutional investors and hedge funds have recently bought and sold shares of the company. Paulson & CO. Inc. grew its position in shares of Bausch Health Cos by 24.0% in the 2nd quarter. Paulson & CO. Inc. now owns 32,791,702 shares of the company’s stock worth $218,393,000 after acquiring an additional 6,352,667 shares in the last quarter. Goldentree Asset Management LP raised its position in shares of Bausch Health Cos by 13.2% during the 2nd quarter. Goldentree Asset Management LP now owns 34,254,889 shares of the company’s stock valued at $227,848,000 after acquiring an additional 4,004,889 shares in the last quarter. MUFG Securities EMEA plc bought a new position in Bausch Health Cos during the second quarter worth $22,644,000. SG Americas Securities LLC boosted its holdings in Bausch Health Cos by 114.4% in the second quarter. SG Americas Securities LLC now owns 6,152,986 shares of the company’s stock worth $40,979,000 after purchasing an additional 3,282,684 shares during the period. Finally, Maple Rock Capital Partners Inc. boosted its holdings in Bausch Health Cos by 14.9% in the second quarter. Maple Rock Capital Partners Inc. now owns 7,808,487 shares of the company’s stock worth $52,005,000 after purchasing an additional 1,010,987 shares during the period. Institutional investors and hedge funds own 78.65% of the company’s stock.

About Bausch Health Cos

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.